期刊
VASCULAR PHARMACOLOGY
卷 51, 期 5-6, 页码 359-364出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.vph.2009.09.005
关键词
Pulmonary hypertension; Argininosuccinate lyase; Argininosuccinate synthetase; Cationic amino acid transporter-1; Arginase
资金
- National Institutes of Health [1K99HL097153]
- Fondation Leducq
- Southeast Affiliates of the American Heart Association [09BGIA2310050]
- Programmatic Development
- Cardiovascular Discovery Institute of the Medical College of Georgia
- AHA Southeast
- [HL60190]
- [HL67841]
- [HL72123]
- [HL70061]
- [HL084739]
- [R21HD057406]
- [HL61284]
Previous studies demonstrate impaired nitric oxide (NO) signaling in children and animal models with congenital heart defects and increased pulmonary blood flow. However, the molecular mechanisms underlying these alterations remain incompletely understood. The purpose of this study was to determine if early changes in arginine metabolic pathways could play a role in the reduced NO signaling demonstrated in our lamb model of congenital heart disease with increased pulmonary blood flow (Shunt lambs). The activities of the arginine recycling enzymes, argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL) were both decreased in lung tissues of Shunt lambs while arginase activity was increased. Associated with these alterations, lung L-arginine levels were decreased. These changes correlated with an increase in NO synthase-derived reactive oxygen species (ROS) generation. This study provides further insights into the molecular mechanisms leading to decreased NO signaling in Shunt lambs and suggests that altered arginine metabolism may play a role in the development of the endothelial dysfunction associated with pulmonary hypertension secondary to increased pulmonary blood flow. (C) 2009 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据